- Home
- ARQT vs IMCR Comparison
ARQT vs IMCR Comparison
Compare ARQT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- IMCR
- Stock Information
- Founded
- ARQT 2016
- IMCR 2008
- Country
- ARQT United States
- IMCR United Kingdom
- Employees
- ARQT N/A
- IMCR N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARQT Health Care
- IMCR Health Care
- Exchange
- ARQT Nasdaq
- IMCR Nasdaq
- Market Cap
- ARQT 1.7B
- IMCR 1.5B
- IPO Year
- ARQT 2020
- IMCR 2021
- Fundamental
- Price
- ARQT $13.04
- IMCR $36.60
- Analyst Decision
- ARQT Strong Buy
- IMCR Buy
- Analyst Count
- ARQT 6
- IMCR 10
- Target Price
- ARQT $18.80
- IMCR $58.13
- AVG Volume (30 Days)
- ARQT 2.1M
- IMCR 419.7K
- Earning Date
- ARQT 05-06-2025
- IMCR 05-07-2025
- Dividend Yield
- ARQT N/A
- IMCR N/A
- EPS Growth
- ARQT N/A
- IMCR N/A
- EPS
- ARQT N/A
- IMCR N/A
- Revenue
- ARQT $212,819,000.00
- IMCR $333,581,000.00
- Revenue This Year
- ARQT $61.15
- IMCR $25.96
- Revenue Next Year
- ARQT $37.98
- IMCR $8.06
- P/E Ratio
- ARQT N/A
- IMCR N/A
- Revenue Growth
- ARQT 100.03
- IMCR 25.75
- 52 Week Low
- ARQT $6.99
- IMCR $23.15
- 52 Week High
- ARQT $17.75
- IMCR $49.05
- Technical
- Relative Strength Index (RSI)
- ARQT 40.51
- IMCR 71.46
- Support Level
- ARQT $13.27
- IMCR $31.14
- Resistance Level
- ARQT $14.30
- IMCR $33.30
- Average True Range (ATR)
- ARQT 0.71
- IMCR 1.94
- MACD
- ARQT -0.07
- IMCR 0.57
- Stochastic Oscillator
- ARQT 10.94
- IMCR 96.12
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.